U.S. markets closed

PolarityTE, Inc. (PTE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1000-0.0700 (-5.98%)
At close: 4:00PM EDT
1.0700 -0.03 (-2.73%)
After hours: 07:38PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.1700
Bid1.1000 x 21500
Ask1.1300 x 3100
Day's Range1.1000 - 1.1600
52 Week Range0.5500 - 2.3800
Avg. Volume3,929,160
Market Cap88.696M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-1.0300
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 12, 2016
1y Target Est2.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is the Options Market Predicting a Spike in PolarityTE (PTE) Stock?

    Is the Options Market Predicting a Spike in PolarityTE (PTE) Stock?

    Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.

  • PolarityTE Stock Drops On Wider Than Expected Q1 Loss, SkinTE Transitions To BLA Pathway

    PolarityTE Stock Drops On Wider Than Expected Q1 Loss, SkinTE Transitions To BLA Pathway

    PolarityTE Inc (NASDAQ: PTE) reported a Q1 EPS loss of $(0.24), missing the consensus of $(0.12) loss, but better than $(0.39) loss a year ago. Sales of $4.71 million increased 31% sequentially and over 400% on a Y/Y basis. SkinTE revenues were up 44% Q/Q to $1.73 million, and Contract services revenues were $2.98 million, compared to $2.39 million in Q4 2020 and $505k in Q1 2020. SkinTE Biologic License Application (BLA) Update: In light of the FDA's announcement related to 'enforcement discretion' that states that 361 HCT/P products will not be extended beyond May 31, the company will now transition to the BLA pathway for SkinTE and will terminate commercial sales of SkinTE and wind down commercial operations. It will file an investigational new drug application (IND) for SkinTE under Section 351 of the Public Health Service Act. Roughly $3.0 million of total property and equipment is related to commercial SkinTE operations, of which the company has determined approximately $2.5 million can be repurposed primarily as R&D equipment. View more earnings on PTE PolarityTE is reiterating its guidance on submitting an IND to the FDA in the second half of 2021. What is the 351 versus 361 Regulatory Framework? The FDA generally regulates regenerative medicine technologies through Sections 351 and 361 of the Public Health Service Act. These two regulatory pathways differ markedly in terms of the time, effort, and expense required to bring a product to market in the U.S. 351 products are regulated as drugs or biologics, while 361 products, comparatively, are largely unregulated. Earlier this week, data from the diabetic foot ulcer trial showed that 70% of patients receiving SkinTE plus SOC had wound closure at 12 weeks versus 34% of patients receiving SOC alone. Price Action: PTE shares dropped 14.5% at $1.06 during the premarket session on the last check Friday. See more from BenzingaClick here for options trades from BenzingaPolarityTE Stock Jumps As SkinTE Aces Diabetic Foot Ulcer Trial© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • PolarityTE, Inc. (PTE) Reports Q1 Loss, Tops Revenue Estimates

    PolarityTE, Inc. (PTE) Reports Q1 Loss, Tops Revenue Estimates

    PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of 7.69% and 88.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?